Skip to main content

Moleculin Biotech, Inc.

corporate_fare Company Profile

Moleculin Biotech, Inc.

MBRX·NASDAQ·Life Sciences·CIK 0001659617

Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on evaluating Annamycin, also known as L-Annamycin and naxtarubicin. The company is conducting a pivotal Phase 3 trial, named "MIRACLE" (Moleculin R/R AML AnnAraC Clinical Evaluation), which combines Annamycin with cytarabine for treating subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). A blinded preliminary data readout for the MIRACLE trial has been released. The company anticipates an interim unblinding of data in mid-2026 and an additional unblinding in the second half of 2026, which will conclude Part A of the two-part trial. Moleculin Biotech, Inc. also maintains two additional technology portfolios targeting hard-to-treat cancers and viruses. These portfolios are supported by clinical and preclinical research funded by investigators at academic institutions. One of these portfolios currently has an ongoing investigator-initiated trial, with another planned, and additional active preclinical testing. Since its inception, drug candidates from each of the three core portfolios are in active planning for, have approval to begin, are currently in, or have successfully completed eighteen clinical trials. All three core technologies are substantially based on discoveries made at, made in conjunction with, and/or licensed from the University of Texas MD Anderson Cancer Center in Houston, Texas. For each core technology, at least one drug candidate has successfully completed a Phase 1 or greater clinical trial. Three of the company's drug candidates have demonstrated human activity in clinical trials and are currently or have been in Phase 1B/2, Phase 2, or Phase 2B/3 clinical trials. Annamycin is one of these drug candidates and is currently in the MIRACLE trial. The company believes Annamycin is a unique DNA binding agent and a "next-generation" anthracycline.

Moleculin Biotech, Inc. (NASDAQ:MBRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 61 items for MBRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for MBRX spans 10-Q, 8-K, DEF 14A, 424B5.

Recent high-impact activity:

  • Moleculin Posts Wider-Than-Expected $9.59/Share Loss as Cash Runs Thin
  • Moleculin 10-Q: $7.3M Cash, Going Concern Doubt, Nasdaq Exception to March 15, 2027
  • Moleculin's Annamycin Interim Data Accepted for ASH; DMC Clears Trial to Continue
  • Annamycin Arms Show 43% and 36% Remission vs 12% Placebo in Pivotal AML Trial
  • Moleculin Completes Part A Dosing in Pivotal MIRACLE AML Trial; Data Due Q1 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$33.56M
Op. Cash Flow
-$22.73M
Free Cash Flow
-$22.73M
Operating Income
-$25.1M
Cash & Equivalents
$8.88M
Debt / Equity
0.00×
Shares Outstanding
3.2M sh
Source: 10-K · filed 2026-04-14 · accession 0001437749-26-012273

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 54,541 shares in MBRX as of the October 30, 2026 settlement, a 56.8% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 13, 2026, 41.2% of MBRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)54,541 shares as of October 30, 2026
Change vs prior period▼ 56.8%
Days to cover1.00 at avg daily volume of 67,646
Daily short volume (FINRA facilities)41.2% of 3,576 shares on November 13, 2026
5-day average short volume51.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for MBRX, detected from its recent SEC filings · based on capital-structure filings through 2026-08-21.

1 recent capital raiseATM program1 shelf registrationreverse split

ATM Offering Size Increased · Shares Sold Under ATM

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with M →
$7.2 -10.63% today
52-week range · as of 2026-11-13 $3.23 – $243.8
Market cap
$8.26M
Volume
9.9K (0.3× avg)
3-mo avg 36.6K
Live data · 2026-11-14 07:28 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MBRX - Latest Insights

MBRX
Nov 13, 2026, 5:46 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.87
Real-time Price: $7.20 info
Change: -$0.6664 (-8%) info
Market Cap: $8.263M info
MBRX
Nov 13, 2026, 4:31 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.87
Real-time Price: $7.20 info
Change: -$0.6664 (-8%) info
Market Cap: $8.263M info
MBRX
Nov 04, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.46
Real-time Price: $7.20 info
Change: -$1.26 (-15%) info
Market Cap: $8.263M info
MBRX
Nov 04, 2026, 11:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $8.20
Real-time Price: $7.20 info
Change: -$0.9921 (-12%) info
Market Cap: $8.263M info
MBRX
Oct 30, 2026, 8:50 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.70
Real-time Price: $7.20 info
Change: -$1.50 (-17%) info
Market Cap: $8.263M info
MBRX
Oct 20, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.280
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Oct 16, 2026, 9:29 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.310
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Oct 16, 2026, 9:20 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3617
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4469
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Sep 29, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.561
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Sep 29, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.560
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Sep 18, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.7671
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Aug 24, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.6099
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Aug 21, 2026, 5:16 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $0.593
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Aug 14, 2026, 5:05 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.6202
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Aug 14, 2026, 8:41 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.581
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Aug 14, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5889
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Aug 13, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.5657
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Aug 03, 2026, 5:11 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.3988
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
MBRX
Aug 03, 2026, 9:47 AM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $0.3037
Real-time Price: $7.20 info
Change: Reverse Stock Split info
Market Cap: $8.263M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets